Mineralys Therapeutics develops targeted medicines addressing hypertension and related conditions such as chronic kidney disease and obstructive sleep apnea, driven by dysregulated aldosterone. Their lead product, lorundrostat, is a selective aldosterone synthase inhibitor that aims to provide an innovative oral solution for these health issues.
No jobs found. Subscribe below to get notified when we find something for you.
Searching